Israel Englander’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.04M | Sell |
131,664
-2,134,310
| -94% | -$13.6M | ﹤0.01% | 4284 |
|
|
2026
Q1 | $13.1M | Buy |
2,265,974
+1,406,923
| +164% | +$9.33M | 0.01% | 1912 |
|
|
2025
Q4 | $6.74M | Buy |
859,051
+334,302
| +64% | +$2.63M | ﹤0.01% | 2686 |
|
|
2025
Q3 | $4.27M | Sell |
524,749
-2,408,871
| -82% | -$16M | ﹤0.01% | 3303 |
|
|
2025
Q2 | $13.7M | Buy |
2,933,620
+615,648
| +27% | +$2.82M | 0.01% | 1942 |
|
|
2025
Q1 | $12.7M | Buy |
2,317,972
+369,420
| +19% | +$1.49M | 0.01% | 1938 |
|
|
2024
Q4 | $6.61M | Buy |
1,948,552
+502,853
| +35% | +$1.62M | ﹤0.01% | 2571 |
|
|
2024
Q3 | $4.12M | Sell |
1,445,699
-250,825
| -15% | -$644K | ﹤0.01% | 3015 |
|
|
2024
Q2 | $3.82M | Buy |
1,696,524
+771
| +0% | +$1.55K | ﹤0.01% | 2970 |
|
|
2024
Q1 | $3.75M | Buy |
1,695,753
+147,798
| +10% | +$382K | ﹤0.01% | 3164 |
|
|
2023
Q4 | $3.64M | Sell |
1,547,955
-726,189
| -32% | -$1.34M | ﹤0.01% | 3070 |
|
|
2023
Q3 | $4.23M | Buy |
2,274,144
+463,797
| +26% | +$1.06M | ﹤0.01% | 2846 |
|
|
2023
Q2 | $4.74M | Buy |
+1,810,347
| New | +$4.61M | ﹤0.01% | 2724 |
|
|
2023
Q1 | – | Sell |
-694,043
| Closed | -$923K | – | 6931 |
|
|
2022
Q4 | $923K | Buy |
+694,043
| New | +$980K | ﹤0.01% | 4243 |
|
|
2022
Q3 | – | Sell |
-552,549
| Closed | -$851K | – | 7557 |
|
|
2022
Q2 | $851K | Sell |
552,549
-883,073
| -62% | -$1.86M | ﹤0.01% | 4523 |
|
|
2022
Q1 | $3.67M | Buy |
1,435,622
+1,214,026
| +548% | +$2.97M | ﹤0.01% | 3271 |
|
|
2021
Q4 | $649K | Sell |
221,596
-4,643
| -2% | -$10K | ﹤0.01% | 4812 |
|
|
2021
Q3 | $554K | Sell |
226,239
-228,298
| -50% | -$663K | ﹤0.01% | 5257 |
|
|
2021
Q2 | $1.85M | Buy |
454,537
+283,142
| +165% | +$1.08M | ﹤0.01% | 4062 |
|
|
2021
Q1 | $773K | Buy |
+171,395
| New | +$924K | ﹤0.01% | 4453 |
|
|
2020
Q4 | – | Sell |
-43,220
| Closed | -$256 | – | 5643 |
|
|
2020
Q3 | $256 | Sell |
43,220
-461,023
| -91% | -$1.84M | ﹤0.01% | 3940 |
|
|
2020
Q2 | $1.34M | Buy |
+504,243
| New | +$1.76M | ﹤0.01% | 2813 |
|
|
2020
Q1 | – | Sell |
-171,460
| Closed | -$1.21M | – | 4578 |
|
|
2019
Q4 | $1.21M | Buy |
171,460
+77,982
| +83% | +$644K | ﹤0.01% | 2912 |
|
|
2019
Q3 | $918K | Buy |
+93,478
| New | +$1.05M | ﹤0.01% | 2899 |
|
|
2019
Q2 | – | Sell |
-120,750
| Closed | -$1.21M | – | 4524 |
|
|
2019
Q1 | $1.21M | Buy |
+120,750
| New | +$1.55M | ﹤0.01% | 2747 |
|
|
2018
Q3 | – | Sell |
-100,000
| Closed | -$1.9M | – | 4322 |
|
|
2018
Q2 | $1.9M | Buy |
+100,000
| New | +$1.94M | ﹤0.01% | 2444 |
|
Other funds holding XERS
RA
Israel Englander's XERS Position: Q2 2026 in Review
Israel Englander reduced its Xeris Biopharma Holdings (XERS) stake by 94% in Q2 2026, selling an estimated $13.6M and leaving 131,664 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4284.
Israel Englander first reported a position in XERS in Q2 2018 and has held it in 26 quarters since. The position peaked at $13.7M in Q2 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Israel Englander held 131,664 shares of Xeris Biopharma Holdings worth $1.04M as of Q2 2026.
- Israel Englander sold 2,134,310 Xeris Biopharma Holdings shares in Q2 2026, an estimated $13.6M.
- Xeris Biopharma Holdings made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4284 holding.
- Israel Englander first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 26 quarters since.
- Israel Englander's Xeris Biopharma Holdings position peaked at $13.7M in Q2 2025.
- 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.